General Information:

Id: 6,301 (click here to show other Interactions for entry)
Diseases: Angioimmunoblastic T-Cell lymphoma
Cancer
Cutaneous T-cell lymphoma
Peripheral T-cell leukemia / lymphoma
Homo sapiens
peripheral T-cell lymphoma
article/cited
Reference: Quesada AE et al.(2014) Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-kappaB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options Int J Clin Exp Pathol 7: 8732-8739 [PMID: 25674239]

Interaction Information:

Comment Panobinostat inhibits Sirt1 pathway.
Formal Description
Interaction-ID: 60069

drug/chemical compound

Panobinostat

decreases_activity of

gene/protein

SIRT1

Comment 10 PTCL patients demonstrated nuclear and cytoplasmic staining (high expression) for p-Akt (Ser 473) and p-mTOR (Ser 2448) corresponding to mTORC 2, and all cases showed strong, diffuse nuclear translocation for p-NF-kappaBp65 (Ser 536). All ten cases also showed cytoplasmic staining for IGF-1R (Tyr1165/1166). In addition, high expression in the tumor cells (>50%) of nuclear Sirt1, and cytoplasmic COX-2 and FASN were detected in PTCL cells in 7, 9 and 8 out of 10 cases, respectively.
Formal Description
Interaction-ID: 60088

disease

Peripheral T-cell leukemia / lymphoma

increases_expression of

gene/protein

SIRT1

Pattern of staining: Nuclear.
Comment Sirt1, reportedly deacetylates Akt and thereby, promotes phosphatidylinositol (3,4,5)-triphosphate binding to Akt and participates in its activation (cited information).
Formal Description
Interaction-ID: 60119

gene/protein

SIRT1

decreases_acetylation of

gene/protein

AKT1

Drugbank entries Show/Hide entries for AKT1
Comment Sirt1, reportedly deacetylates Akt and thereby, promotes phosphatidylinositol (3,4,5)-triphosphate binding to Akt and participates in its activation (cited information).
Formal Description
Interaction-ID: 60139

gene/protein

SIRT1

increases_activity of

gene/protein

AKT1

via promoting phosphatidylinositol (3,4,5)-triphosphate binding to Akt.
Drugbank entries Show/Hide entries for AKT1
Comment Vorinostat is able to dephosphorylate Akt on serine 473 by increasing the activity of protein phosphatase 1 (PP1), to downregulate SIRT1 mRNA, and to reduce Sirt1 deacetylase activity (cited information).
Formal Description
Interaction-ID: 60156

drug/chemical compound

Vorinostat

decreases_activity of

gene/protein

SIRT1

of SIRT1 mRNA and Sirt1 deacetylase activity.
Drugbank entries Show/Hide entries for Vorinostat
Comment A patient with AITL (Angioimmunoblastic T-Cell Lymphoma, a rare, aggressive (fast-growing) form of peripheral T-cell lymphoma (PTCL)) showed a remarkable durable response using a combination of conventional CHOP and bortezomib. All seven markers (p-mTOR (Ser 2448), p-Akt (Ser 473), p-NF-kappaBp65 (Ser 536), COX2, Bcl-2, FASN, and Sirt1) were highly expressed, indicating expressing constitutive activation of the mTORC2/NF-kappaB pathway in this patient who responded remarkably well to an NF-kappaB antagonist.
Formal Description
Interaction-ID: 60191

disease

Angioimmunoblastic T-Cell lymphoma

increases_expression of

gene/protein

SIRT1